Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the potential benefit of primary tumor surgery for patients with breast cancer.
Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.
Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.
Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.
Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.
Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.
Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses emerging subtypes of pancreatic cancer.
James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the role of radiotherapy in oligometastatic non–small cell lung cancer (NSCLC).
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.
Jeffrey S. Weber, MD, PhD, the Laura and Isaac Perlmutter Professor of Oncology, co-director of the Melanoma Research Program, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, and a 2016 Giant of Cancer Care® in Melanoma, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.
Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the future of biosimilars in oncology.
Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses advances in imaging for prostate cancer.
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.
Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the evolution of PD-1/PD-L1 inhibitors in the treatment of patients with hematologic malignancies.
Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.
Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.
Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses multiparametric assays in breast cancer.
Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses advancements in mantle cell lymphoma.
John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the prognosis of patients with chronic lymphocytic leukemia.
Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the potential benefit of using biosimilars in the treatment of patients with breast cancer.
Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical use of biosimilars in oncology.
Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.
Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.
Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.
Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).
Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).
Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.
David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.
